Calithera Biosciences, Inc (CALA)

Oncology Corporate Profile

Stock Performance

10.6500
0.0000

HQ Location

343 Oyster Point Blvd., Suite 200
South San Francisco, CA 94080

Company Description

Calithera Biosciences, Inc. is a clinical-stage company focused on the discovery, development and commercialization of first-in-class small molecule oncology therapeutics.  The company is building a pipeline of targeted anti-cancer compounds that inhibit pathways critical to tumor growth and survival.  Calithera's lead clinical candidate, CB-839, blocks glutaminase, an enzyme critical to tumor metabolism, and is currently being tested in patients with advanced solid and hematological cancers.  

Website: http://www.calithera.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
CB-839 (+ nivolumab)glutaminase inhibitorRenal cell carcinoma (RCC)IBristol-Myers Squibb
CB-839glutaminase inhibitorVarious cancer typesI
CB-1158Arginase inhibitorVarious cancer typesI
HPP607hexokinase II inhibitorVarious cancer typesPreclinical

View additional information on product candidates here »

Pipeline image

Source


http://www.calithera.com/

Recent News Headlines

Calithera to Receive $12 Million Milestone Payment From Incyte for Achievement of Pharmacokinetic and Pharmacodynamic Goals in Phase 1 Study

3/28/2017 11:00 am

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 28, 2017-- Calithera Biosciences, Inc., a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor ...

Calithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares

3/27/2017 08:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 27, 2017-- Calithera Biosciences, Inc., a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor ...

Calithera Biosciences, Inc. Prices Public Offering of 6,830,000 shares of Common Stock

3/22/2017 11:00 am

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 22, 2017-- Calithera Biosciences, Inc., a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor ...

Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock

3/20/2017 08:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 20, 2017-- Calithera Biosciences, Inc., a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor ...

Calithera reports 4Q loss

3/16/2017 09:03 pm

Calithera reports 4Q loss

3/16/2017 09:03 pm

Calithera Biosciences Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights

3/16/2017 08:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 16, 2017-- Calithera Biosciences, Inc., a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor ...

Calithera Biosciences to Report Fourth Quarter and Year-End 2016 Financial Results on Thursday, March 16, 2017

3/10/2017 12:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 10, 2017-- Calithera Biosciences, Inc., a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor ...

Calithera Biosciences to Present at Cowen and Company 37th Annual Health Care Conference

3/1/2017 12:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 01, 2017-- Calithera Biosciences, Inc., a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor ...

Calithera Biosciences to Present at the BIO CEO & Investor and Leerink Global Healthcare Conferences in February

2/9/2017 12:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Feb. 09, 2017-- Calithera Biosciences, Inc., a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor ...

Biotech Acquisitions on the Rise in 2017: Latest Reports on Calithera Biosciences and Evoke Pharma

1/31/2017 02:03 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 31, 2017 / Biotech acquisitions deals are expected to see a substantial jump in 2017 as large pharmaceutical companies look to boost slowing revenues. In January we ...